Improvement of Dissolution and Bioavailability of Nitrendipine by Inclusion in Hydroxypropyl-β-cyclodextrin

References

• Lôftsson T., Fridriksdottir H., Olafsdottir B., Gudmundsson O. Solubilization and stabilization of drugs through cyclodextrin complexation. Acta Pharm. Nord. 1991; 3: 215–217
   Google Scholar
• Lôftsson T., Brewester M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996; 85: 1097–1025
   Google Scholar
• Antoniadou-Vyza E., Buckton G., Michaleas S.G., Loukas Y.L., Efentakis M. The formation of an inclusion complex of methocarbamol with hydroxypropyl-β-cyclodextrin: the effect on chemical stability, solubility and dissolution rate. Int. J. Pharm. 1997; 158: 233–239
   Web of Science ®Google Scholar
• Davis N.M., Wang G., Tucker I.G. Evaluation of a hydrocortisone/hydroxypropyl- β-cyclodextrin solution for ocular drug delivery. Int. J. Pharm. 1997; 156: 201–209
   Google Scholar
• Kaukonen A.M., Kilpeläinen I., Mannermaa J.-P. Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: solubilization and stability of spironolactone in solutions of β-cyclodextrin derivatives. Int. J. Pharm. 1997; 159: 159–170
   Google Scholar
• Loukas Y.L., Vraka V., Gregoriadis G. Drugs, in cyclodextrins, in liposomes: a novel approach to the chemical stability of drugs sensitive to hydrolysis. Int. J. Pharm. 1998; 162: 137–142
   Web of Science ®Google Scholar
• Montassier P., Duchêne D., Poelman M.-C. Inclusion complexes of tretinoin with cyclodextrins. Int. J. Pharm. 1997; 153: 199–209
   Web of Science ®Google Scholar
• Linares M., de Bertorello M.M., Longhi M. Solubilization of naphthoquinones by complexation with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 1997; 159: 13–18
   Web of Science ®Google Scholar
• Becket G., Schep L.J., Tan M.Y. Improvement of the in vitro dissolution of praziquantel by complexation with α-, β-, and γ-cyclodextrins. Int. J. Pharm. 1991; 179: 65–71
   Google Scholar
• Ficarra R., Ficarra P., Di Bella M.R., Raneri D., Tommasini S., Calabrò M.L., Villari A., Coppolino S. Study of the inclusion complex of atenolol with β-cyclodextrin. J. Pharm. Biomed. Anal. 2000; 23: 231–236
   PubMed Web of Science ®Google Scholar
• Özkan Y., Atay T., Dikmen N., Işimer A., Aboul-Enein H.Y. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with β-cyclodextrin. Pharmaceutica Acta Helvetiae. 2000; 74: 365–370
   PubMedGoogle Scholar
• Espinar F.J.O., Iged S.A., Mendez J.B., Jato J.L. Reduction in the ulcerogenicity of naproxen by complexation with β-cyclodextrin. Int. J. Pharm. 1991; 70: 35–41
   Google Scholar
• Kimura E., Bersani-Amado C.A., Sudo S.U., Santos S.R.J., Oga S. Pharmacokinetic profile of piroxicam-β-cyclodextrin, in rat plasma and lymph. General Pharmacol. 1997; 28: 695–698
   PubMedGoogle Scholar
• Wong J.W., Yuen K.H. Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrin. Int. J. Pharm. 2001; 227: 177–185
   PubMed Web of Science ®Google Scholar
• Ahmed M.O., El-Gibaly I., Ahmed S.M. Effects of cyclodextrins on the physicochemical properties and antimycotic activity of clotrimazole. Int. J. Pharm. 1998; 171: 111–121
   Web of Science ®Google Scholar
• Veiga F., Fernandes C., Teixeira F. Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. Int. J. Pharm. 2000; 202: 165–171
   PubMed Web of Science ®Google Scholar
• Latrofa A., Trapani G., Franco M., Serra M., Muggironi M., Fanizzi F.P., Cutrignelli A., Liso G. Complexation of phenytoin with some hydrophilic cyclodextrins: effect on aqueous solubility, dissolution rate, and anticonvulsant activity in mice. Eur. J. Pharm. Biopharm. 2001; 52: 65–73
   PubMed Web of Science ®Google Scholar
• Müller B., Brauns V. Solubilization of drugs by modified β-cyclodextrins. Int. J. Pharm. 1985; 26: 77–88
   Web of Science ®Google Scholar
• Pitha J., Milecki J., Fales H., Pannell L., Uekama K. Hydroxypropyl-β-cyclodextrin: preparation and characterization effects on solubility of drugs. Int. J. Pharm. 1986; 29: 73–82
   Web of Science ®Google Scholar
• Backensfeld T., Müller B., Kolter K. Interaction of NSA with cyclodextrins and hydroxypropyl-cyclodextrin derivatives. Int. J. Pharm. 1988; 46: 217–222
   Google Scholar
• Szente L., Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 1999; 14: 17–28
   Google Scholar
• Stoepel K., Heise A., Kazda S. Pharmacological studies of the antihypertensive effect of nitrendipine. Arzneim Forsch. 1981; 31: 2056–2061
   PubMed Web of Science ®Google Scholar
• Santiago T.M., Lopez L.M. Nitrendipine: a new dihydropyridine calcium channel antagonist for the treatment of hypertension. Ann. Pharmacother. 1990; 24: 167–175
   Web of Science ®Google Scholar
• Knorr K., Stoepel K. Effect of a new calcium antagonist, nitrendipine, on blood pressure and heart rate of conscious, unrestrained dogs. Arzneim Forsch. 1981; 31: 2062–2064
   PubMed Web of Science ®Google Scholar
• Muller F., Bolli P., Erne P., Block L., Kiowsky W., Buhler F. Antihypertensive therapy with the long-acting calcium antagonist nitrendipine. J. Cardiovas. Pharmacol. 1984; 6: s173–s176
   Google Scholar
• Schneeweiss A. Cardiovascular drugs in children: Angiotensin-converting enzyme inhibitors. Pediatr. Cardiol. 1988; 9: 109–15
   PubMed Web of Science ®Google Scholar
• Kristl A., Primožič S., Strojan P., Kozjek F. Modifizierter freigabetest nach USP für nitrendipin-tabletten. Pharmazie 1992; 47: 704–706
   Google Scholar
• Krol G.J., Lettieri J.T., Yeh S.C., Burkholder D.E., Birkett J.P. Disposition and pharmacokinetics of 14C-nitrendipine in healthy volunteers. J. Cardiovas. Pharmacol. 1987; 9: s122–s128
   Google Scholar
• Goda K.L., Sorkin E.M. Nitrendipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1987; 33: 123–155
   PubMed Web of Science ®Google Scholar
• Moyano J.R., Arias-Blanco M.J., Ginés J.M., Giordano F. Solid-state characterization and dissolution characteristics of gliclazide-β-cyclodextrin inclusion complexes. Int. J. Pharm. 1997; 148: 211–217
   Web of Science ®Google Scholar
• Vianna R.F.L., Bentley M.V.L.B., Ribeiro G., Carvalho F.S., Neto A.F., de Oliveira D.C.R., Collett J.H. Formation of cyclodextrin inclusion complexes with corticosteroids: their characterization and stability. Int. J. Pharm. 1998; 167: 205–213
   Web of Science ®Google Scholar
• Nagase Y., Hirata M., Wada K., Arima H., Hirayama F., Irie T., Kikuchi M., Uekama K. Improvement of some pharmaceutical properties DY-9760e by sulfobutyl ether β-cyclodextrin. Int. J. Pharm. 2000; 229: 163–172
   Google Scholar
• Nikova T., Shekerdzhiiski R., Yamboliev I. Formulation of solid dosage form of nitrendipine. Formatsiya 1991; 41: 23–29
   Google Scholar
• Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 1971; 60: 1281–1302
   PubMed Web of Science ®Google Scholar
• Higuchi T., Conners K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrument. 1965; 117–212
   Google Scholar
• Grant D.J.W., Higuchi W. Solubility behaviour of organic compounds. Techniques of Chemistry, A. Weissberger. Wiley, New York 1990; Vol. 21: 440–473
   Google Scholar
• Upton R.A. Simple and reliable method for serial sampling of blood from rats. J. Pharm. Sci. 1975; 64: 112–114
   PubMed Web of Science ®Google Scholar
• Weiner D.L. Design and analysis of bioavailability studies. Statistics in the Pharmaceutical Industry, C.R. Bucncher, J.Y. Tsay. Marcel Dekker, Inc., New York 1981; 205–229
   Google Scholar
• Shargel L., Yu A.B.C. Applied Biopharmaceutics and Pharmacokinetics, 3rd Ed. Prentice-Hall, New York 1993; 47–76
   Google Scholar
• Raemsch K.D., Sommer J. Pharmacokinetics and metabolism of nitrendipine. Nitrendipine 1984; 409–422
   Google Scholar
• Bőcker R.H., Preuss E., Peter R. High-performance liquid chromatography of the metabolites of nitrendipine and investigation into the metabolic pathways of this dihydropyridine. J. Chromatogr. 1990; 530: 206–211
   PubMed Web of Science ®Google Scholar
• Ei-Mahrouk G.M., Al-Angary A.A., Al-Meshal M.A. Modified β-cyclodextrin lorazepam inclusion complexation. Die Pharm. Ind. 1994; 56: 1080–1084
   Web of Science ®Google Scholar
• Gandhi R.B., Karara A.H. Characterization, dissolution, and diffusion properties of tolbutamide-β-cyclodextrin complex system. Drug Dev. Ind. Pharm. 1988; 14: 657–682
   Web of Science ®Google Scholar
• Hassan M.A., Suleiman M.S., Najib N.M. Improvement of the in vitro dissolution characteristics of famotidine by inclusion in β-cyclodextrins. Int. J. Pharm. 1990; 58: 19–24
   Google Scholar
• Stella V.J., Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997; 14: 556–567
   PubMed Web of Science ®Google Scholar
• Ventura C.A., Tirendi S., Puglisi G., Bousquet E., Panza L. Improvements of water solubility and dissolution rate of ursodeoxycholic acid and chenodeoxycholic acid by complexation with natural and modified β-cyclodextrins. Int. J. Pharm. 1997; 149: 1–13
   Web of Science ®Google Scholar
• Becket G., Schep L.J., Tan M.Y. Improvement of the in vitro dissolution of praziquantel by complexation with α-, β-, and γ-cyclodextrins. Int. J. Pharm. 1999; 179: 65–71
   PubMed Web of Science ®Google Scholar